It is with great pleasure that we announce the reinforcement of our collaboration about lung cancer between HCS Pharma and TARGET team of the OncoLille Institute (Team “Efficacy and resistance to anti-tumor targeted therapies”, CANTHER UMR9020, Lille, France).
Initially supported by Région Hauts-de-France, this project has been initiated in spring 2021 under the supervision of Dr. Zoulika Kherrouche (Institut Pasteur de Lille and OncoLille) and Dr. Véronique De Conto (HCS Pharma). The Plan France Relance supported by french National Research Agency (ANR) promotes the insertion of young researchers in Research and Development. In this way it has allowed the recruitment of a PhD, Marie Fernandes, for the overall management of the project during 2 years since October 2022.
The objective of this project is to develop a complex 3D assay using BIOMIMESYS® matrix in order to evaluate the efficacy of multiple targeted therapies on different models of oncogenic alterations in lung cancer, and to better characterize mechanisms of resistance to these therapies. In addition, this model will allow to reduce animal testing. The overall goal is thus to identify the best therapy for a patient in a relevant in vitro model. Therefore, it is essential to develop a complex model associating the tumor cells, the fibroblastic stromal cells and the extra-cellular matrix (ECM) whose rigidity and composition are altered in the context of cancer/tumour development. This is precisely why we wish to create this model using BIOMIMESYS® hydroscaffold, a hyaluronic-acid based hydroscaffold™ grafted with structural components that mimics the extracellular matrix and in which the composition and the stiffness are modular to be as close of possible to pathophysiological/tumoral structure of the lung.
Feel free to contact us if you want more information about BIOMIMESYS® hydroscaffold™ or about our services in phenotypic screening.
0 Comments